Arthur He's Stock Ratings

HC Wainwright & Co. Analyst

Arthur He is an analyst at HC Wainwright & Co.. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/07/2024

Overall Average Return

4.25%

Smart Score

53.1%

Overall Average Return Percentile

48th

Number of Ratings

44
Buy NowGet Alert
06/28/2024ADAGBuy Now
Adagene
$2.6687.97%—ReiteratesBuy → BuyGet Alert
06/28/2024LVTXBuy Now
LAVA Therapeutics
$1.97204.57%$6 → $6ReiteratesBuy → BuyGet Alert
06/05/2024HOOKBuy Now
HOOKIPA Pharma
$0.531042.64%$5 → $6MaintainsBuyGet Alert
05/28/2024CALTBuy Now
Calliditas Therapeutics
$39.08-0.2% → $39DowngradeBuy → NeutralGet Alert
05/24/2024CALTBuy Now
Calliditas Therapeutics
$39.0815.15%$50 → $45MaintainsBuyGet Alert
05/22/2024PSTXBuy Now
Poseida Therapeutics
$2.97573.4% → $20ReiteratesBuy → BuyGet Alert
05/20/2024SLDBBuy Now
Solid Biosciences
$6.70138.81% → $16ReiteratesBuy → BuyGet Alert
05/20/2024PRMEBuy Now
Prime Medicine
$5.5281.16% → $10Initiates → BuyGet Alert
05/15/2024BCABBuy Now
BioAtla
$1.37410.95% → $7ReiteratesBuy → BuyGet Alert
05/02/2024PSTXBuy Now
Poseida Therapeutics
$2.97573.4% → $20ReiteratesBuy → BuyGet Alert
04/26/2024HOOKBuy Now
HOOKIPA Pharma
$0.53852.2%$6.5 → $5MaintainsBuyGet Alert
04/22/2024PSTXBuy Now
Poseida Therapeutics
$2.97573.4% → $20ReiteratesBuy → BuyGet Alert
04/15/2024MSCLBuy Now
Satellos Bioscience
—— → $1.2Initiates → BuyGet Alert
03/27/2024BCABBuy Now
BioAtla
$1.37410.95%$10 → $7MaintainsBuyGet Alert
03/25/2024HOOKBuy Now
HOOKIPA Pharma
$0.531137.86% → $6.5ReiteratesBuy → BuyGet Alert
03/21/2024LVTXBuy Now
LAVA Therapeutics
$1.97204.57% → $6ReiteratesBuy → BuyGet Alert
03/14/2024SLDBBuy Now
Solid Biosciences
$6.70138.81% → $16ReiteratesBuy → BuyGet Alert
03/11/2024SLDBBuy Now
Solid Biosciences
$6.70138.81%$9 → $16MaintainsBuyGet Alert
03/08/2024PSTXBuy Now
Poseida Therapeutics
$2.97573.4% → $20ReiteratesBuy → BuyGet Alert
02/22/2024CALTBuy Now
Calliditas Therapeutics
$39.0827.94% → $50ReiteratesBuy → BuyGet Alert
12/11/2023PSTXBuy Now
Poseida Therapeutics
$2.97573.4%$15 → $20MaintainsBuyGet Alert
11/27/2023CALTBuy Now
Calliditas Therapeutics
$39.0827.94% → $50ReiteratesBuy → BuyGet Alert
11/17/2023LVTXBuy Now
LAVA Therapeutics
$1.97204.57% → $6ReiteratesBuy → BuyGet Alert
11/08/2023BCABBuy Now
BioAtla
$1.37629.93%$17 → $10MaintainsBuyGet Alert
10/04/2023ADAGBuy Now
Adagene
$2.6687.97% → $5ReiteratesBuy → BuyGet Alert
09/01/2023ADAGBuy Now
Adagene
$2.6687.97% → $5ReiteratesBuy → BuyGet Alert
08/23/2023LVTXBuy Now
LAVA Therapeutics
$1.97204.57%$9 → $6MaintainsBuyGet Alert
08/11/2023HOOKBuy Now
HOOKIPA Pharma
$0.531137.86%$8 → $6.5MaintainsBuyGet Alert
08/08/2023PSTXBuy Now
Poseida Therapeutics
$2.97405.05% → $15ReiteratesBuy → BuyGet Alert
08/02/2023BCABBuy Now
BioAtla
$1.371140.88% → $17ReiteratesBuy → BuyGet Alert
06/12/2023LVTXBuy Now
LAVA Therapeutics
$1.97356.85% → $9ReiteratesBuy → BuyGet Alert
05/23/2023PSTXBuy Now
Poseida Therapeutics
$2.97405.05% → $15ReiteratesBuy → BuyGet Alert
05/15/2023BCABBuy Now
BioAtla
$1.371140.88% → $17ReiteratesBuy → BuyGet Alert
05/12/2023HOOKBuy Now
HOOKIPA Pharma
$0.531423.52% → $8ReiteratesBuy → BuyGet Alert
05/10/2023PSTXBuy Now
Poseida Therapeutics
$2.97405.05% → $15Reiterates → BuyGet Alert
04/21/2023ADAGBuy Now
Adagene
$2.6687.97% → $5Reiterates → BuyGet Alert
04/13/2023LVTXBuy Now
LAVA Therapeutics
$1.97356.85% → $9Reiterates → BuyGet Alert
03/29/2023ADAGBuy Now
Adagene
$2.6687.97% → $5Reiterates → BuyGet Alert
03/24/2023BCABBuy Now
BioAtla
$1.371140.88%$20 → $17MaintainsBuyGet Alert
03/21/2023ADAGBuy Now
Adagene
$2.6687.97% → $5Reiterates → BuyGet Alert
03/16/2023HOOKBuy Now
HOOKIPA Pharma
$0.531423.52% → $8Reiterates → BuyGet Alert
03/10/2023PSTXBuy Now
Poseida Therapeutics
$2.97405.05% → $15Reiterates → BuyGet Alert
02/23/2023PSTXBuy Now
Poseida Therapeutics
$2.97405.05% → $15MaintainsBuyGet Alert
10/25/2022LVTXBuy Now
LAVA Therapeutics
$1.97356.85% → $9Initiates → BuyGet Alert

Recent Analyst Stock Rating News

Crypto's Active Uses Limited To Bitcoin Hodling And Meme Coin Gambling, Trader Questions Real World Utility
Capriole Fund founder Charles Edwards expressed skepticism about the practical uses of cryptocurrencies in 2024. He questioned the real-world application of Solana (CRYPTO: SOL), Ethereum (CRYPTO: ETH), and others.
Arthur Hayes Says 'Bitcoin Is Superior, Whereas Gold Is Inferior' — Here's Why
Arthur Hayes, co-founder of cryptocurrency exchange BitMEX, made a bold statement claiming that Bitcoin (CRYPTO: BTC) is a better safe-haven asset than gold. 
Is Dogecoin's 10% Rally The Start Of Something Big?
Dogecoin (CRYPTO: DOGE) is rallying on increasing whale transactions, prompting fresh optimistic takes from traders about its upcoming price trajectory.
Bitcoin Spot ETFs See $146M Outflows On Monday For 5th Outflow Day In 6
Bitcoin (CRYPTO: BTC) spot Exchange-Traded Funds (ETFs) experienced net outflows totaling $146 million on June 17.
Is $0.10 Really Dogecoin's 'Next Stop'?
Dogecoin (CRYPTO: DOGE) is facing downwards price pressure, leading traders to question how much DOGE could drop.
Dogecoin, Shiba Inu, Floki Are 'Dino Coins,' Says Trader: He Likes These 3 Other Meme Coins As 'Blue Chips'
Pseudonymous trader ‘Trading Vapor‘ suggested meme coins are poised to benefit the most from the upcoming alt season.
Benzinga Bulls And Bears: GameStop, Apple, Tesla, Bitcoin And Raoul Pal's Dogecoin ETF Prediction
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Bitcoin, Ethereum, Dogecoin Drop Further: 'Chop For Rest Of The Summer…Beggars Can't Be Choosers,' Says Trader
Cryptocurrency markets are trading in the red, with Bitcoin touching the sensitive $65,000 level and mixed opinions about future price trajectory.
What's Next For Bitcoin? 'Bounce Incoming,' Says One Trader But Not Everyone Agrees
Bitcoin's (CRYPTO: BTC) price volatility has attracted contrary trader opinions for its upcoming price trajectory.
Arthur Hayes, Raoul Pal Predict Dogecoin ETF: 'If People Wait In Line For Luxury Brands, They Will Trade Meme Coins Online'
BitMex co-founder Arthur Hayes and macro guru Raoul Pal shared their thoughts on the future of digital assets and market strategies in a recent podcast, delivering important insights on what to expect in the
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free